EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial

Jay P Reddy, Alexander D Sherry, Bryan Fellman, Suyu Liu, Tharakeswara Bathala, Cara Haymaker, Lorenzo Cohen, Benjamin D Smith, David Ramirez, Simona F Shaitelman, Stephen G Chun, Marina Medina-Rosales und 12 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025-03 · 121 (4) · 885-893

DOI: 10.1016/j.ijrobp.2024.10.030 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025-03. Verfasst von Jay P Reddy und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jreddy@mdanderson.org. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Metastasis, Standard of Care. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Prior evidence suggests a progression-free survival (PFS) benefit from adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy for patients with some oligometastatic solid tumors. Randomized trials testing this hypothesis in breast cancer have yet to be published. We sought to determine whether adding MDT to SOC systemic therapy improves PFS in oligometastatic breast cancer. METHODS AND MATERIALS: External Beam Radiation to Eliminate Nominal Metastatic Disease is a multicenter phase 2 randomized basket trial testing the addition of MDT to SOC systemic therapy in patients with ≤5 metastases (NCT03599765). Patients were randomly assigned 1:1 to MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy) or to SOC systemic therapy-only. Primary endpoint was PFS, and secondary endpoints included overall survival, time to subsequent line of systemic therapy, and time to the appearance of new metastases. Exploratory analyses included quality of life and systemic immune response measures. RESULTS: From September 2018 through July 2022, 22 and 21 patients were randomly assigned to the MDT and no-MDT arms, respectively. At a median follow-up of 24.8 months, PFS was not improved with the addition of MDT to SOC systemic therapy (median PFS 15.6 months MDT vs 24.9 months no-MDT [hazard ratio, 0.91; 95% CI, 0.34-2.48; P = .86]). Similarly, MDT did not improve overall survival, time to subsequent line of systemic therapy, or time to the appearance of new metastases (all P > .05). No significant differences were found in quality of life measures, systemic T-cell activation, or T-cell stimulatory cytokine concentration. CONCLUSIONS: Among patients with oligometastatic breast cancer, the addition of MDT to SOC systemic therapy did not improve PFS. These findings suggest that MDT may have no systemic benefit in otherwise unselected patients with oligometastatic breast cancer, although this trial was limited by a heterogeneous and small sample size and overperformance of both treatment arms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm MetastasisStandard of CareHumansFemaleMiddle AgedAgedAdultQuality of LifeProgression-Free Survival

Autor:innen und Institutionen

  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jreddy@mdanderson.org.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Reddy, J. P., Sherry, A. D., Fellman, B., Liu, S., Bathala, T., Haymaker, C., Cohen, L., Smith, B. D., Ramirez, D., Shaitelman, S. F., Chun, S. G., Medina-Rosales, M., Teshome, M., Brewster, A., Barcenas, C. H., Reuben, A., Ghia, A. J., Ludmir, E. B., Weed, D., …, & Tang, C. (2025). Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics, 121(4), 885-893. https://doi.org/10.1016/j.ijrobp.2024.10.030

Vancouver

Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, et al. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2025;121(4):885-893. doi:10.1016/j.ijrobp.2024.10.030

BibTeX
@article{Reddy2025,
  author = {Reddy, Jay P and Sherry, Alexander D and Fellman, Bryan and Liu, Suyu and Bathala, Tharakeswara and Haymaker, Cara and Cohen, Lorenzo and Smith, Benjamin D and Ramirez, David and Shaitelman, Simona F and Chun, Stephen G and Medina-Rosales, Marina and Teshome, Mediget and Brewster, Abenaa and Barcenas, Carlos H and Reuben, Alexandre and Ghia, Amol J and Ludmir, Ethan B and Weed, Daniel and Shah, Shalin J and Mitchell, Melissa P and Woodward, Wendy A and Gomez, Daniel R and Tang, Chad},
  title = {Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  volume = {121},
  number = {4},
  pages = {885--893},
  doi = {10.1016/j.ijrobp.2024.10.030}
}
Kostenlos starten →